← Back to Search

Imaging

Optical Coherence Tomography for Early-Stage Pancreatic Cancer

N/A
Recruiting
Led By Mary Dillhoff, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Immediate surgery cohort: Adult patients with pancreatic cancer or IPMN
Adult patients undergoing pancreatic resection for a presumed IPMN
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This trialtests a new imaging tech to detect small pancreatic cancer in people with the disease. It may help accurately identify cancer in resected tissue.

Who is the study for?
This trial is for adults with pancreatic cancer or intraductal papillary mucinous neoplasm (IPMN) who are scheduled for immediate surgery. Participants must provide informed consent to join the study. Pregnant individuals cannot participate.Check my eligibility
What is being tested?
The study is testing ultra-high resolution optical coherence tomography, a high-tech imaging technique, to see if it can detect very small early-stage pancreatic cancers in tissue removed during surgery.See study design
What are the potential side effects?
Since this trial involves diagnostic imaging and not drug treatment, there are no direct side effects like those associated with medications. However, standard risks of surgical procedures apply.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Adult patients with pancreatic cancer or IPMN who need surgery right away.
Select...
Adults having surgery to remove a suspected IPMN in the pancreas.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measure accuracy of using OCT to diagnose pancreatic cancer and compare with histology.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (resection, OCT)Experimental Treatment3 Interventions
Participants undergo resection. Resected tissues are analyzed via ultra-high resolution OCT.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Optical Coherence Tomography
2016
Completed Phase 2
~1510
Therapeutic Conventional Surgery
2005
Completed Phase 3
~9860

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
316 Previous Clinical Trials
289,611 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,603 Previous Clinical Trials
40,913,200 Total Patients Enrolled
Mary Dillhoff, MDPrincipal Investigator - Ohio State University Comprehensive Cancer Center
Ohio State University Hospital - Wexner Medical Center, Richard M. Ross Heart Hospital
University Of Cincinnati College Of Medicine (Medical School)
1 Previous Clinical Trials
7 Total Patients Enrolled

Media Library

Ultra-High Resolution Optical Coherence Tomography (Imaging) Clinical Trial Eligibility Overview. Trial Name: NCT03711890 — N/A
Pancreatic Cancer Research Study Groups: Diagnostic (resection, OCT)
Pancreatic Cancer Clinical Trial 2023: Ultra-High Resolution Optical Coherence Tomography Highlights & Side Effects. Trial Name: NCT03711890 — N/A
Ultra-High Resolution Optical Coherence Tomography (Imaging) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03711890 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants is the clinical trial currently accommodating?

"Affirmative. Clinicaltrials.gov presents evidence that this experiment is currently attempting to recruit participants, with the first post being on March 26th 2019 and the latest edit occurring on November 22nd 2022. In total, 75 individuals are needed from one medical facility."

Answered by AI

Is this research initiative currently seeking participants?

"Clinicaltrials.gov notes that this study is accepting participants, having been first published on March 26th 2019 and most recently revised on November 22nd 2022."

Answered by AI
~12 spots leftby Mar 2025